Database: Botulinum toxin

nvcg1NVCG Commissie Wetenschap

Database: Botulinum toxin

 

 

  1. Zarone, F., et al., Treatment Concept for a Patient with a High Smile Line and Gingival Pigmentation: A Case Report. Int J Periodontics Restorative Dent, 2017. 37(2): p. e142-e148.
  2. Wollina, U. and A. Goldman, Botulinum toxin A and/or soft tissue fillers for facial rehabilitation. Wien Med Wochenschr, 2017. 167(3-4): p. 92-95.
  3. Szuch, E., et al., Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity. Clin Neurol Neurosurg, 2017. 156: p. 1-3.
  4. Sapra, P., et al., A Single-blind, Split-face, Randomized, Pilot Study Comparing the Effects of Intradermal and Intramuscular Injection of Two Commercially Available Botulinum Toxin A Formulas to Reduce Signs of Facial Aging. J Clin Aesthet Dermatol, 2017. 10(2): p. 34-44.
  5. Prager, W., D. Nogueira Teixeira, and P.S. Leventhal, IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials. Dermatol Surg, 2017.
  6. Pelle-Ceravolo, M. and M. Angelini, Transcutaneous Brow Shaping: A Straightforward and Precise Method to Lift and Shape the Eyebrows. Aesthet Surg J, 2017.
  7. Ma, F., et al., Ultrastructural changes in human masseter muscles after botulinum neurotoxin a injection. Muscle Nerve, 2017.
  8. Kim, N.H., et al., A Simplified Approach to Botulinum Toxin Injection for the Lower Face: Concept of a 24-Hour Clock. Plast Reconstr Surg, 2017. 139(3): p. 816e-818e.
  9. Kaplan, J.B., Consideration of Muscle Depth for Botulinum Toxin Injections: A Three-Dimensional Approach. Plast Surg Nurs, 2017. 37(1): p. 32-38.
  10. Jiang, H., J. Zhou, and S. Chen, Different Glabellar Contraction Patterns in Chinese and Efficacy of Botulinum Toxin Type A for Treating Glabellar Lines: A Pilot Study. Dermatol Surg, 2017.
  11. Hur, M.S., Anatomical relationships of the procerus with the nasal ala and the nasal muscles: transverse part of the nasalis and levator labii superioris alaeque nasi. Surg Radiol Anat, 2017.
  12. Franca, K., et al., The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr, 2017.
  13. Fouche, J.J., et al., Left/Right Pain Asymmetry With Injectable Cosmetic Treatments for the Face. Aesthet Surg J, 2017.
  14. De la Torre Canales, G., et al., Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review. Clin Oral Investig, 2017. 21(3): p. 727-734.
  15. Consideration of Muscle Depth for Botulinum Toxin Injections: A Three-Dimensional Approach. Plast Surg Nurs, 2017. 37(1): p. E2.
  16. Zhu, J., et al., The Efficacy and Safety of Fractional CO2 Laser Combined with Topical Type A Botulinum Toxin for Facial Rejuvenation: A Randomized Controlled Split-Face Study. Biomed Res Int, 2016. 2016: p. 3853754.
  17. Westbrook, A.D., A Practical Guide to Botulinum Toxin Procedures. Fam Med, 2016. 48(3): p. 234-5.
  18. Vanaman, M.M.D., S.G.M.D.F.F. Fabi, and S.E.M.D. Cox, Neck Rejuvenation Using a Combination Approach: Our Experience and a Review of the Literature. Dermatologic Surgery, 2016. 42 Supplement(2): p. S94-S100.
  19. Sundaram, H., et al., Global Aesthetics Consensus: Botulinum Toxin Type A–Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg, 2016. 137(3): p. 518e-529e.
  20. Sundaram, H., et al., Global Aesthetics Consensus: Botulinum Toxin Type A-Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast Reconstr Surg, 2016. 137(3): p. 518e-29e.
  21. Sundaram, H., et al., Global Aesthetics Consensus: Hyaluronic Acid Fillers and Botulinum Toxin Type A-Recommendations for Combined Treatment and Optimizing Outcomes in Diverse Patient Populations. Plast Reconstr Surg, 2016. 137(5): p. 1410-23.
  22. Sundaram, H., et al., Aesthetic Applications of Botulinum Toxin A in Asians: An International, Multidisciplinary, Pan-Asian Consensus. Plast Reconstr Surg Glob Open, 2016. 4(12): p. e872.
  23. Singh, S., S. Kaur, and P. Wilson, Plantar hyperhidrosis: A review of current management. J Dermatolog Treat, 2016: p. 1-6.
  24. Scherer, M.A., Specific aspects of a combined approach to male face correction: botulinum toxin A and volumetric fillers. J Cosmet Dermatol, 2016. 15(4): p. 566-574.
  25. Scaglione, F., Conversion Ratio between Botox((R)), Dysport((R)), and Xeomin((R)) in Clinical Practice. Toxins (Basel), 2016. 8(3).
  26. Narurkar, V.A.M.D., et al., A Comprehensive Approach to Multimodal Facial Aesthetic Treatment: Injection Techniques and Treatment Characteristics From the HARMONY Study. Dermatologic Surgery, 2016. 42 Supplement(2): p. S177-S191.
  27. Nair, K.P., Review of Manual of Botulinum Toxin Therapy, 2nd ed. JAMA Neurol, 2016. 73(3): p. 359.
  28. Min, P., et al., Alteration of Skin Mechanical Properties in Patients Undergoing Botulinum Toxin Type A Injections of Forehead Rhytides. Aesthetic Plast Surg, 2016.
  29. Mahmoud, B.H., et al., Prospective Randomized Split-Face Comparative Study Between Topical Botulinum Toxin A Surface Application and Local Injection for Crow’s Feet. Dermatol Surg, 2016. 42(4): p. 554-6.
  30. Lee, S.-K.M.D.P. and H.S.M.D.P. Kim, Asymmetry and Maldistribution of Polyacrylamide Hydrogel Filler in the Infraorbital Area Successfully Managed With Botulinum Toxin A Treatment. Dermatologic Surgery, 2016. 42(12): p. 1395-1397.
  31. Lee, M.J., et al., Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study. J Neurol Sci, 2016. 363: p. 51-4.
  32. Langelier, N.M.D., K.M.D. Beleznay, and J.M.D. Woodward, Rejuvenation of the Upper Face and Periocular Region: Combining Neuromodulator, Facial Filler, Laser, Light, and Energy-Based Therapies for Optimal Results. Dermatologic Surgery, 2016. 42 Supplement(2): p. S77-S82.
  33. Kuwahara, H. and R. Ogawa, Using a Vibration Device to Ease Pain During Facial Needling and Injection. Eplasty, 2016. 16: p. e9.
  34. Kucuker, I., et al., The Effect of Chemodenervation by Botulinum Neurotoxin on the Degradation of Hyaluronic Acid Fillers: An Experimental Study. Plast Reconstr Surg, 2016. 137(1): p. 109-13.
  35. Kollewe, K., et al., Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting. J Neural Transm (Vienna), 2016.
  36. Kaplan, J.B., The Dilution Confusion: Easy Dosing for Botulinum Toxins. Plast Surg Nurs, 2016. 36(1): p. 24-7.
  37. Hwang, C.J., Periorbital Injectables: Understanding and Avoiding Complications. J Cutan Aesthet Surg, 2016. 9(2): p. 73-9.
  38. Humphrey, S.M.D.F.F., K.M.D.F.F. Beleznay, and R.M.D.F.F. Fitzgerald, Combination Therapy in Midfacial Rejuvenation. Dermatologic Surgery, 2016. 42 Supplement(2): p. S83-S88.
  39. Gupta, A.K.M.D.P.F. and J.P. Carviel, A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. Dermatologic Surgery, 2016. 42(12): p. 1335-1339.
  40. Fraint, A., P. Vittal, and C. Comella, Considerations on patient-related outcomes with the use of botulinum toxins: is switching products safe? Ther Clin Risk Manag, 2016. 12: p. 147-54.
  41. Fabi, S.G.M.D., et al., Combining Microfocused Ultrasound With Botulinum Toxin and Temporary and Semi-Permanent Dermal Fillers: Safety and Current Use. Dermatologic Surgery, 2016. 42 Supplement(2): p. S168-S176.
  42. Fabi, S.G.M.D. and J.M.D. Carruthers, Single Modality Approach to Rejuvenate the Aging Face and Body: A Thing of the Past? Dermatologic Surgery, 2016. 42 Supplement(2): p. S73-S76.
  43. Fabi, S.G., et al., Consensus Recommendations for Combined Aesthetic Interventions Using Botulinum Toxin, Fillers, and Microfocused Ultrasound in the Neck, Decolletage, Hands, and Other Areas of the Body. Dermatol Surg, 2016. 42(10): p. 1199-1208.
  44. Dressler, D., F. Adib Saberi, and H. Bigalke, Botulinum toxin therapy: reduction of injection site pain by pH normalisation. J Neural Transm (Vienna), 2016.
  45. Dayan, S.M.D., Combination Therapies: A Personal Perspective on the Practice Building Benefits. Dermatologic Surgery, 2016. 42 Supplement(2): p. S165-S167.
  46. Carruthers, J.M.D.F. and A.M.D.F. Carruthers, A Multimodal Approach to Rejuvenation of the Lower Face. Dermatologic Surgery, 2016. 42 Supplement(2): p. S89-S93.
  47. Carruthers, J., et al., Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices. Dermatol Surg, 2016. 42(5): p. 586-97.
  48. Bonaparte, J.P., et al., A Comparative Assessment of Three Formulations of Botulinum Toxin Type A for Facial Rhytides: A Systematic Review with Meta-Analyses. Plast Reconstr Surg, 2016. 137(4): p. 1125-40.
  49. Black, J.M.M.D., T.M.D. Pavicic, and D.H.M.D. Jones, Tempering Patient Expectations and Working With Budgetary Constraints When It Comes to a Single Versus a Multimodal Approach. Dermatologic Surgery, 2016. 42 Supplement(2): p. S161-S164.
  50. Alvarenga, A., et al., BOTOX-A injection of salivary glands for drooling. J Pediatr Surg, 2016.
  51. Yiannakopoulou, E., Serious and long-term adverse events associated with the therapeutic and cosmetic use of botulinum toxin. Pharmacology, 2015. 95(1-2): p. 65-9.
  52. Wu, D.C., S.G. Fabi, and M.P. Goldman, Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck–Lower Face. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 76S-79S.
  53. Trevidic, P., J. Sykes, and G. Criollo-Lamilla, Anatomy of the Lower Face and Botulinum Toxin Injections. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 84S-91S.
  54. Sykes, J.M., et al., Newer Understanding of Specific Anatomic Targets in the Aging Face as Applied to Injectables: Facial Muscles–Identifying Optimal Targets for Neuromodulators. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 56S-61S.
  55. Rohrich, R.J., The “Soft-Tissue Fillers and Neuromodulators: International and Multidisciplinary Perspectives” Supplement. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 1S-3S.
  56. Ricci, L.H., et al., Ocular adverse effects after facial cosmetic procedures: a review of case reports. J Cosmet Dermatol, 2015.
  57. Punga, A.R., A. Eriksson, and M. Alimohammadi, Regional Diffusion of Botulinum Toxin in Facial Muscles: A Rando-mised Double-blind Study and a Consideration for Clinical Studies with Split-face Design. Acta Derm Venereol, 2015.
  58. Paracka, L., et al., Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. J Neural Transm, 2015.
  59. Nahabet, E., J.E. Janis, and B. Guyuron, Neurotoxins: Expanding Uses of Neuromodulators in Medicine–Headache. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 104S-110S.
  60. Monheit, G., Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck–Upper Face (Glabella, Forehead, and Crow’s Feet). Plast Reconstr Surg, 2015. 136(5 Suppl): p. 72S-75S.
  61. Michaud, T., V. Gassia, and L. Belhaouari, Facial dynamics and emotional expressions in facial aging treatments. J Cosmet Dermatol, 2015. 14(1): p. 9-21.
  62. Levy, P.M., Neurotoxins: Current Concepts in Cosmetic Use on the Face and Neck–Jawline Contouring/Platysma Bands/Necklace Lines. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 80S-83S.
  63. Lee, H.H., et al., Effect of a Second Injection of Botulinum Toxin on Lower Facial Contouring, as Evaluated Using 3-Dimensional Laser Scanning. Dermatol Surg, 2015.
  64. Lam, S.M., R. Glasgold, and M. Glasgold, Analysis of Facial Aesthetics as Applied to Injectables. Plast Reconstr Surg, 2015. 136(5 Suppl): p. 11S-21S.
  65. Kim, J.E., et al., The efficacy and safety of liquid-type botulinum toxin type a for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg, 2015. 135(3): p. 732-41.
  66. Keaney, T., Male aesthetics. Skin Therapy Lett, 2015. 20(2): p. 5-7.
  67. Kang, A., E. Burns, and D.A. Glaser, Botulinum toxin A for palmar hyperhidrosis: associated pain, duration, and reasons for discontinuation of therapy. Dermatol Surg, 2015. 41(2): p. 297-8.
  68. Guerrrerosantos, J., et al., Effectiveness of botulinum toxin (type-a) administered by the fixed-site dosing approach versus the muscle area identification. Aesthetic Plast Surg, 2015. 39(2): p. 243-51.
  69. Alam, M., et al., Consensus statement regarding storage and reuse of previously reconstituted neuromodulators. Dermatol Surg, 2015. 41(3): p. 321-6.
  70. Schlessinger, J., et al., Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study. Dermatol Surg, 2014. 40(2): p. 176-83.
  71. Nayyar, P., et al., BOTOX: Broadening the Horizon of Dentistry. J Clin Diagn Res, 2014. 8(12): p. ZE25-9.
  72. Montaser-Kouhsari, L., et al., Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial. J Dermatolog Treat, 2014. 25(4): p. 337-41.
  73. Malcmacher, L., Botoxonomics. The economics of adding Botox and dermal fillers to your practice. J N J Dent Assoc, 2014. 85(4): p. 16-7.
  74. Lee, J.H., et al., Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. J Dermatolog Treat, 2014. 25(4): p. 326-30.
  75. Kouris, A., et al., Muscle weakness in treatment of palmar hyperhidrosis with botulinum toxin type a: can it be prevented? J Drugs Dermatol, 2014. 13(11): p. 1315-6.
  76. Kim, B.W., et al., Adverse events associated with botulinum toxin injection: a multidepartment, retrospective study of 5310 treatments administered to 1819 patients. J Dermatolog Treat, 2014. 25(4): p. 331-6.
  77. Jiang, H.Y., et al., Diffusion of two botulinum toxins type A on the forehead: double-blinded, randomized, controlled study. Dermatol Surg, 2014. 40(2): p. 184-92.
  78. Torrisi, B.M., et al., Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin. J Control Release, 2013. 165(2): p. 146-52.
  79. Sheen-Ophir, S. and Y. Almog, [Diplopia following subcutaneous injections of botulinum toxin for cosmetic or medical use]. Harefuah, 2013. 152(2): p. 98-100, 123, 122.
  80. Rzany, B., et al., Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications. J Drugs Dermatol, 2013. 12(1): p. 80-4.
  81. Ramirez-Castaneda, J., et al., Diffusion, spread, and migration of botulinum toxin. Mov Disord, 2013.
  82. Prager, W., Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines. Clin Pharmacol, 2013. 5: p. 39-52.
  83. Persaud, R., et al., An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep, 2013. 4(2): p. 10.
  84. Naumann, M., et al., Immunogenicity of botulinum toxins. J Neural Transm, 2013. 120(2): p. 275-90.
  85. Loyo, M. and T.C. Kontis, Cosmetic botulinum toxin: has it replaced more invasive facial procedures? Facial Plast Surg Clin North Am, 2013. 21(2): p. 285-98.
  86. Lee, S.H., et al., Abobotulinum toxin A and onabotulinum toxin A for masseteric hypertrophy: a split-face study in 25 Korean patients. J Dermatolog Treat, 2013. 24(2): p. 133-6.
  87. Korman, J.B., H.R. Jalian, and M.M. Avram, Analysis of Botulinum Toxin Products and Litigation in the United States. Dermatol Surg, 2013.
  88. Kirby, J.S., C.N. Adgerson, and B.E. Anderson, A survey of dermatology resident education in cosmetic procedures. J Am Acad Dermatol, 2013. 68(2): p. e23-8.
  89. Kim, B.W., et al., Adverse events associated with botulinum toxin injection: A multidepartment, retrospective study of 5310 treatments administered to 1819 patients. J Dermatolog Treat, 2013.
  90. Khan, T.T., et al., Facial blanching due to neurotoxins: proposed mechanisms. Dermatol Surg, 2013. 39(1 Pt 1): p. 24-9.
  91. Kerscher, M., Y. Yutskovskaya, and T.C. Flynn, IncobotulinumtoxinA in esthetics. J Drugs Dermatol, 2013. 12(6): p. e111-20.
  92. Keaney, T.C. and T.S. Alster, Botulinum toxin in men: review of relevant anatomy and clinical trial data. Dermatol Surg, 2013. 39(10): p. 1434-43.
  93. Jones, D., Gentlemen, relax: commentary on botulinum toxin in men: a review of relevant anatomy and clinical trial data. Dermatol Surg, 2013. 39(10): p. 1444-5.
  94. Jandhyala, R., Improving consent procedures and evaluation of treatment success in cosmetic use of incobotulinumtoxinA: an assessment of the treat-to-goal approach. J Drugs Dermatol, 2013. 12(1): p. 72-8.
  95. Hexsel, D., et al., Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol Surg, 2013. 39(7): p. 1088-96.
  96. Hanke, C.W., et al., A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg, 2013. 39(6): p. 891-9.
  97. Hamilton, H.K. and K.A. Arndt, When is “too early” too early to start cosmetic procedures? JAMA Dermatol, 2013. 149(11): p. 1271.
  98. Gu, S. and R. Jin, Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol, 2013. 364: p. 21-44.
  99. Finzi, E., Antidepressant effects of botulinum toxin A: scientific rationale. J Psychiatry Neurosci, 2013. 38(5): p. E29.
  100. Cigna, E., et al., The use of botulinum toxin in the treatment of plunging nose: cosmetic results and a functional serendipity. Clin Ter, 2013. 164(2): p. e107-13.
  101. Chen, J.J. and K. Dashtipour, Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer. Pharmacotherapy, 2013. 33(3): p. 304-18.
  102. Carruthers, J., et al., The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine–a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg, 2013. 39(3 Pt 2): p. 510-25.
  103. Carruthers, A., et al., The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine–a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice. Dermatol Surg, 2013. 39(3 Pt 2): p. 493-509.
  104. Bryant, A.M., et al., Molecular composition and extinction coefficient of native botulinum neurotoxin complex produced by Clostridium botulinum hall A strain. Protein J, 2013. 32(2): p. 106-17.
  105. Bonaparte, J.P., et al., A comparative assessment of three formulations of botulinum toxin A for facial rhytides: a systematic review and meta-analyses. Syst Rev, 2013. 2: p. 40.
  106. Banegas, R.A., et al., The South American Glabellar Experience Study (SAGE): A Multicenter Retrospective Analysis of Real-World Treatment Patterns Following the Introduction of IncobotulinumtoxinA in Argentina. Aesthet Surg J, 2013.
  107. Alimohammadi, M., M. Andersson, and A.R. Punga, Correlation of Botulinum Toxin Dose with Neurophysiological Parameters of Efficacy and Safety in the Glabellar Muscles: A Double-blind, Placebo-controlled, Randomized Study. Acta Derm Venereol, 2013.
  108. Alaraj, A.M., D.T. Oystreck, and T.M. Bosley, Variable ptosis after botulinum toxin type a injection with positive ice test mimicking ocular myasthenia gravis. J Neuroophthalmol, 2013. 33(2): p. 169-71.
  109. Al Hamdan, E.M., et al., Knowledge and attitude of dentists towards the use of botulinum toxin and dermal fillers in dentistry, Riyadh, Saudi Arabia. J Cosmet Laser Ther, 2013. 15(1): p. 46-54.
  110. Ahn, C.S., et al., Cosmetic Procedures Performed in the United States: A 16-Year Analysis. Dermatol Surg, 2013.
  111. Yu, K.C., et al., Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg, 2012. 14(3): p. 198-204.
  112. Yamauchi, P.S., Soft tissue filler and botulinum toxin treatment techniques. G Ital Dermatol Venereol, 2012. 147(1): p. 29-44.
  113. Thomas, M.K., J.A. D’Silva, and A.J. Borole, Facial sculpting: Comprehensive approach for aesthetic correction of round face. Indian J Plast Surg, 2012. 45(1): p. 122-7.
  114. Taylor, S.C., et al., AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data. Dermatol Surg, 2012. 38(11): p. 1804-11.
  115. Schulte, D., The Michigan Board of Dentistry’s Botox Statement: what does it mean? J Mich Dent Assoc, 2012. 94(5): p. 20-1.
  116. Pontes, H.A., et al., Uncommon foreign body reaction caused by botulinum toxin. J Craniofac Surg, 2012. 23(4): p. e303-5.
  117. Pickett, A., Inability of speculation to explain dose effect differences between botulinum toxin products. Arch Facial Plast Surg, 2012. 14(6): p. 467-8.
  118. Pellett, S., Learning from the past: historical aspects of bacterial toxins as pharmaceuticals. Curr Opin Microbiol, 2012. 15(3): p. 292-9.
  119. Pearlman, S.J., et al., Physician confidence in fillers and neurotoxins: a national survey. Arch Facial Plast Surg, 2012. 14(1): p. 67-8.
  120. Park, D.H., et al., Analysis of the patterns of lateral canthal rhytids and reference for botulinum toxin treatment in orientals. Aesthetic Plast Surg, 2012. 36(5): p. 1211-5.
  121. Nguyen, A.T., et al., Cosmetic medicine: facial resurfacing and injectables. Plast Reconstr Surg, 2012. 129(1): p. 142e-153e.
  122. Nettar, K. and C. Maas, Facial filler and neurotoxin complications. Facial Plast Surg, 2012. 28(3): p. 288-93.
  123. Moers-Carpi, M., et al., A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. J Cosmet Laser Ther, 2012. 14(6): p. 296-303.
  124. Marinelli, C., Comments on state’s botox statement. J Mich Dent Assoc, 2012. 94(7): p. 10.
  125. Maas, C., et al., Current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review. Aesthet Surg J, 2012. 32(1 Suppl): p. 8S-29S.
  126. Luebberding, S. and M. Alexiades-Armenakas, Safety of dermal fillers. J Drugs Dermatol, 2012. 11(9): p. 1053-8.
  127. Lewis, M.B., Exploring the positive and negative implications of facial feedback. Emotion, 2012. 12(4): p. 852-9.
  128. Levy, L.L. and J.J. Emer, Complications of minimally invasive cosmetic procedures: prevention and management. J Cutan Aesthet Surg, 2012. 5(2): p. 121-32.
  129. Lee, S.K., Multiple intradermal small bolus injection of botulinum toxin: the limit and the potentiality. J Cosmet Laser Ther, 2012. 14(6): p. 304-6.
  130. Koshy, J.C., et al., Effect of dietary zinc and phytase supplementation on botulinum toxin treatments. J Drugs Dermatol, 2012. 11(4): p. 507-12.
  131. Kerscher, M., et al., Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res, 2012. 304(2): p. 155-61.
  132. Katona, P., Botulinum toxin: therapeutic agent to cosmetic enhancement to lethal biothreat. Anaerobe, 2012. 18(2): p. 240-3.
  133. Kane, M.A., et al., Development and validation of a new clinically-meaningful rating scale for measuring lateral canthal line severity. Aesthet Surg J, 2012. 32(3): p. 275-85.
  134. Jung, C.H., et al., A botulinum neurotoxin-like function of Potentilla chinensis extract that inhibits neuronal SNARE complex formation, membrane fusion, neuroexocytosis, and muscle contraction. Pharm Biol, 2012. 50(9): p. 1157-67.
  135. Jandhyala, R., Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence. J Drugs Dermatol, 2012. 11(6): p. 731-6.
  136. Jandhyala, R., Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact. J Plast Reconstr Aesthet Surg, 2012. 65(6): p. 720-31.
  137. Jablonka, E.M., D.A. Sherris, and H.G. Gassner, Botulinum toxin to minimize facial scarring. Facial Plast Surg, 2012. 28(5): p. 525-35.
  138. Isaac, C.R., M.R. Chalita, and L.D. Pinto, Botox(R) after Botox(R) – a new approach to treat diplopia secondary to cosmetic botulinic toxin use: case reports. Arq Bras Oftalmol, 2012. 75(3): p. 213-4.
  139. Glogau, R., et al., OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines. Dermatol Surg, 2012. 38(11): p. 1794-803.
  140. Fukamizu, H., et al., Development of a three-microneedle device for hypodermic drug delivery and clinical application. Plast Reconstr Surg, 2012. 130(2): p. 451-5.
  141. Flynn, T.C., Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol, 2012. 11(1): p. 42-50.
  142. Fernandez-Salas, E., et al., Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One, 2012. 7(11): p. e49516.
  143. Conkling, N., et al., Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity? Ann Plast Surg, 2012. 69(4): p. 350-5.
  144. Chen, S., Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel), 2012. 4(10): p. 913-39.
  145. Casas, L.A., Introduction to: current aesthetic use of abobotulinumtoxinA in clinical practice: an evidence-based consensus review. Aesthet Surg J, 2012. 32(1 Suppl): p. 7S.
  146. Brun, C. and J.G. Brock-Utne, Paralyzed by beauty. J Clin Anesth, 2012. 24(1): p. 77-8.
  147. Blugerman, G., D. Schavelzon, and J. Alvarez, Near-infrared imaging of veins in facial injection of botulinum toxin and hyaluronic acid. Dermatol Surg, 2012. 38(7 Pt 2): p. 1252-3.
  148. Berry, M.G. and J.J. Stanek, Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg, 2012. 65(10): p. 1283-91.
  149. Berros, P., et al., Oculofacial contour asymmetries: Management of combined treatment with hyalurostructure and botulinum toxin injections. J Cosmet Laser Ther, 2012. 14(2): p. 111-6.
  150. Benecke, R., Clinical relevance of botulinum toxin immunogenicity. BioDrugs, 2012. 26(2): p. e1-9.

update: June 2017

NVCG congres 28 november 2020